Morgan Stanley’s Grace Therapeutics GRCE Stock Holding History

Morgan Stanley’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.1K	Sell	4,548 -20,900	-82%	-$82.1K	﹤0.01%	6706
2025 Q4	$88K	Buy	25,448 +23,600	+1,277%	+$75K	﹤0.01%	6253
2025 Q3	$5.5K	Hold	1,848	–	–	﹤0.01%	7063
2025 Q2	$5.49K	Hold	1,848	–	–	﹤0.01%	7011
2025 Q1	$4.21K	Sell	1,848 -34	-2%	-$107	﹤0.01%	7025
2024 Q4	$7.04K	Hold	1,882	–	–	﹤0.01%	6911
2024 Q3	$5.65K	Hold	1,882	–	–	﹤0.01%	6882
2024 Q2	$5.5K	Hold	1,882	–	–	﹤0.01%	6825
2024 Q1	$6.45K	Sell	1,882 -1,882	-50%	-$5.55K	﹤0.01%	6828
2023 Q4	$10.9K	Buy	3,764 +1,882	+100%	+$4.46K	﹤0.01%	6817
2023 Q3	$5.24K	Sell	1,882 -1	-0.1%	-$2	﹤0.01%	6907
2023 Q2	$5.93K	Hold	1,883	–	–	﹤0.01%	6948
2023 Q1	$5.2K	Hold	1,883	–	–	﹤0.01%	7042
2022 Q4	$5.66K	Hold	1,883	–	–	﹤0.01%	7114
2022 Q3	$6K	Sell	1,883 -1,228	-39%	-$6.05K	﹤0.01%	7224
2022 Q2	$16K	Sell	3,111 -5,966	-66%	-$36.3K	﹤0.01%	7079
2022 Q1	$66K	Buy	9,077 +3,522	+63%	+$25.1K	﹤0.01%	6558
2021 Q4	$42K	Buy	5,555 +3,097	+126%	+$27.9K	﹤0.01%	6897
2021 Q3	$29K	Sell	2,458 -1,273	-34%	-$25.1K	﹤0.01%	6950
2021 Q2	$101K	Sell	3,731 -4,161	-53%	-$101K	﹤0.01%	6354
2021 Q1	$227K	Buy	7,892 +7,091	+885%	+$246K	﹤0.01%	5589
2020 Q4	$13K	Buy	801 +8	+1%	+$92	﹤0.01%	6571
2020 Q3	$8K	Sell	793 -623	-44%	-$16.2K	﹤0.01%	6341
2020 Q2	$32K	Sell	1,416 -1,934	-58%	-$56.4K	﹤0.01%	5852
2020 Q1	$61K	Sell	3,350 -367	-10%	-$13K	﹤0.01%	5391
2019 Q4	$437K	Buy	3,717 +3,503	+1,637%	+$346K	﹤0.01%	4998
2019 Q3	$19K	Sell	214 -738	-78%	-$68.4K	﹤0.01%	6033
2019 Q2	$52K	Buy	952 +162	+21%	+$7.12K	﹤0.01%	5584
2019 Q1	$39K	Hold	790	–	–	﹤0.01%	5774
2018 Q4	$32K	Sell	790 -43	-5%	-$1.88K	﹤0.01%	5899
2018 Q3	$52K	Hold	833	–	–	﹤0.01%	5871
2018 Q2	$23K	Hold	833	–	–	﹤0.01%	6119
2018 Q1	$41K	Hold	833	–	–	﹤0.01%	5937
2017 Q4	$38K	Buy	833 +818	+5,453%	+$55K	﹤0.01%	5908
2017 Q3	$1K	Buy	+15	New	+$943	﹤0.01%	6472
2016 Q2	–	Hold	0	–	–	–	6678
2016 Q1	–	Hold	0	–	–	–	6740
2015 Q4	–	Hold	0	–	–	–	6822
2015 Q3	–	Hold	0	–	–	–	6744
2015 Q2	–	Hold	0	–	–	–	6768
2015 Q1	–	Hold	0	–	–	–	6675
2014 Q4	–	Hold	0	–	–	–	6687
2014 Q3	–	Hold	0	–	–	–	6674
2014 Q2	–	Hold	0	–	–	–	6612
2014 Q1	–	Hold	0	–	–	–	6554

Other funds holding GRCE

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Morgan Stanley's GRCE Position: Q1 2026 in Review

Morgan Stanley reduced its Grace Therapeutics (GRCE) stake by 82% in Q1 2026, selling an estimated $82.1K and leaving 4,548 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6706.

Morgan Stanley first reported a position in GRCE in Q3 2017 and has held it in 35 quarters since. The position peaked at $437K in Q4 2019. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

Morgan Stanley held 4,548 shares of Grace Therapeutics worth $21.1K as of Q1 2026.
Morgan Stanley sold 20,900 Grace Therapeutics shares in Q1 2026, an estimated $82.1K.
Grace Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6706 holding.
Morgan Stanley first reported a position in Grace Therapeutics in Q3 2017 and has held it in 35 quarters since.
Morgan Stanley's Grace Therapeutics position peaked at $437K in Q4 2019.
34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.